Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD: A UK Biobank Study.

IF 6 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Liver International Pub Date : 2024-11-15 DOI:10.1111/liv.16159

Josh Bilson, Theresa J Hydes, Declan McDonnell, Ryan M Buchanan, Eleonora Scorletti, Alessandro Mantovani, Giovanni Targher, Christopher D Byrne

{"title":"Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD: A UK Biobank Study.","authors":"Josh Bilson, Theresa J Hydes, Declan McDonnell, Ryan M Buchanan, Eleonora Scorletti, Alessandro Mantovani, Giovanni Targher, Christopher D Byrne","doi":"10.1111/liv.16159","DOIUrl":null,"url":null,"abstract":"Background and aims: The impact of metabolic syndrome (MetS) traits on chronic kidney disease (CKD) risk in metabolic dysfunction-associated steatotic liver disease (MASLD) is unknown. We investigated the impact of type and number of MetS traits and liver fibrosis on prevalent CKD and incident end-stage renal disease (ESRD) risk in SLD.Methods: 234 488 UK Biobank participants' were analysed. Hepatic steatosis index (> 36 for SLD, < 30 for no SLD) and MRI-proton density fat fraction (≥ 5.56%) were used to identify SLD. MetS traits were identified using MASLD criteria. Advanced fibrosis (FIB-4 score > 2.67) was determined using FIB-4 scores. eGFR < 60 mL/min/1.73 m2 or albuminuria > 3 mg/mmol identified prevalent CKD. A validated algorithm identified incident ESRD. Binary logistic and Cox regressions were used to test associations with prevalent CKD ([adjusted odds ratios (ORs)]) and incident ESRD (adjusted hazard ratios [HRs]) respectively.Results: 102 410 participants (41.2%) had SLD. 64.4% had MetS. 1.3% had FIB-4 score > 2.67. With SLD and only one MetS trait, hypertension (OR 1.35, 95% CI 1.35-1.72) or type 2 diabetes (T2D) (OR 1.89, 95% CI 1.06-3.38) increased risk of prevalent CKD. MetS (≥ 3 traits) increased prevalent CKD risk (OR 1.94, 95% CI 1.75-2.15), which was further increased by advanced liver fibrosis (OR 4.29, 95% CI 3.36-5.47). CKD prevalence increased with increasing MetS traits. Over 13.6 years (median follow-up), MetS was associated with increased risk of developing ESRD (HR 1.70, 95% CI 1.19-2.43).Conclusions: In MASLD, hypertension, and T2D, number of MetS traits and liver fibrosis increased risk of prevalent CKD and presence of MetS increased the risk of incident ESRD.","PeriodicalId":18101,"journal":{"name":"Liver International","volume":" ","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/liv.16159","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aims: The impact of metabolic syndrome (MetS) traits on chronic kidney disease (CKD) risk in metabolic dysfunction-associated steatotic liver disease (MASLD) is unknown. We investigated the impact of type and number of MetS traits and liver fibrosis on prevalent CKD and incident end-stage renal disease (ESRD) risk in SLD.

Methods: 234 488 UK Biobank participants' were analysed. Hepatic steatosis index (> 36 for SLD, < 30 for no SLD) and MRI-proton density fat fraction (≥ 5.56%) were used to identify SLD. MetS traits were identified using MASLD criteria. Advanced fibrosis (FIB-4 score > 2.67) was determined using FIB-4 scores. eGFR < 60 mL/min/1.73 m² or albuminuria > 3 mg/mmol identified prevalent CKD. A validated algorithm identified incident ESRD. Binary logistic and Cox regressions were used to test associations with prevalent CKD ([adjusted odds ratios (ORs)]) and incident ESRD (adjusted hazard ratios [HRs]) respectively.

Results: 102 410 participants (41.2%) had SLD. 64.4% had MetS. 1.3% had FIB-4 score > 2.67. With SLD and only one MetS trait, hypertension (OR 1.35, 95% CI 1.35-1.72) or type 2 diabetes (T2D) (OR 1.89, 95% CI 1.06-3.38) increased risk of prevalent CKD. MetS (≥ 3 traits) increased prevalent CKD risk (OR 1.94, 95% CI 1.75-2.15), which was further increased by advanced liver fibrosis (OR 4.29, 95% CI 3.36-5.47). CKD prevalence increased with increasing MetS traits. Over 13.6 years (median follow-up), MetS was associated with increased risk of developing ESRD (HR 1.70, 95% CI 1.19-2.43).

Conclusions: In MASLD, hypertension, and T2D, number of MetS traits and liver fibrosis increased risk of prevalent CKD and presence of MetS increased the risk of incident ESRD.

查看原文本刊更多论文

代谢综合征特征对 MASLD 患者肾病风险的影响：英国生物库研究。

背景和目的：代谢综合征（MetS）特征对代谢功能障碍相关性脂肪性肝病（MASLD）中慢性肾病（CKD）风险的影响尚不清楚。我们研究了代谢综合征特征的类型和数量以及肝纤维化对代谢性脂肪肝中慢性肾脏病（CKD）发病率和终末期肾病（ESRD）发病风险的影响。使用 FIB-4 评分确定肝脏脂肪变性指数（SLD > 36，2.67），eGFR 2 或白蛋白尿 > 3 mg/mmol 确定流行性 CKD。经过验证的算法确定了ESRD事件。采用二元逻辑回归和 Cox 回归分别检验与流行性 CKD（[调整后的几率比 (ORs)]）和事件性 ESRD（调整后的危险比 [HRs]）的关联：102 410 名参与者（41.2%）患有 SLD，64.4%患有 MetS。64.4% 患有 MetS。1.3%的人FIB-4评分大于2.67。如果 SLD 只具有一种 MetS 特征，高血压（OR 1.35，95% CI 1.35-1.72）或 2 型糖尿病（T2D）（OR 1.89，95% CI 1.06-3.38）会增加慢性肾脏病的患病风险。MetS（≥ 3 个特征）会增加慢性肾脏病的患病风险（OR 1.94，95% CI 1.75-2.15），而晚期肝纤维化会进一步增加患病风险（OR 4.29，95% CI 3.36-5.47）。随着 MetS 特征的增加，慢性肾脏病的患病率也随之增加。在13.6年（中位随访时间）的随访中，MetS与ESRD发病风险的增加有关（HR 1.70，95% CI 1.19-2.43）：结论：在MASLD、高血压和T2D患者中，MetS特征的数量和肝纤维化会增加慢性肾脏病的发病风险，而MetS的存在会增加ESRD的发病风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Liver International 医学-胃肠肝病学

CiteScore

13.90

自引率

4.50%

发文量

348

审稿时长

2 months

期刊介绍： Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.